Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel and Pegvisomant Co-administration in Acromegaly
NCT00383708Phase 3Completed
- Sponsor
- Ipsen
- Start
- Oct 2006
- Primary completion
- Oct 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of lanreotide and pegvisomant in acromegaly, sponsored by Ipsen. Primary endpoints: Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period at Week 44, Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Previous Treatment and by Final Dose of… at Week 44 and 1 more. Started Oct 2006; status: completed.
02
Drugs
lanreotidepegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00383708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383708.